The Prolow Density Lipoprotein Receptor Related Protein 1 pipeline drugs market research report outlays comprehensive information on the Prolow Density Lipoprotein Receptor Related Protein 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Prolow Density Lipoprotein Receptor Related Protein 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
The report also covers products from therapy areas such as Central Nervous System, Ophthalmology, Immunology, and Metabolic Disorders which include the indications Alzheimer’s Disease, Multiple Sclerosis, Optic Nerve Injury, Glaucoma, Autoimmune Disorders, Pemphigus Vulgaris, Type 1 Diabetes (Juvenile Diabetes), and Type 2 Diabetes. It also reviews key players involved in Prolow Density Lipoprotein Receptor Related Protein 1 targeted therapeutics development with respective active and dormant or discontinued products.
The Prolow Density Lipoprotein Receptor Related Protein 1 pipeline targets constitutes close to five molecules. Out of which, approximately five molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, and Preclinical stages are 1, and 4 respectively.
Prolow Density Lipoprotein Receptor Related Protein 1 overview
Low density lipoprotein receptor-related protein 1 (LRP1), also known as alpha-2-macroglobulin receptor (A2MR), is a protein forming a receptor found in the plasma membrane of cells involved in receptor-mediated endocytosis. This gene encodes a member of the low-density lipoprotein receptor family of proteins. This receptor is involved in several cellular processes, including intracellular signaling, lipid homeostasis, and clearance of apoptotic cells.
For a complete picture of Prolow Density Lipoprotein Receptor Related Protein 1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.